Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.
Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.
复制标题
DOI：
10.1007/s00234-016-1769-8
复制
发表时间：
2017-03
期刊：
影响因子：
2.8
通讯作者：
Young GS
中科院分区：
文献类型：
--
作者：
Qin L;Li X;Stroiney A;Qu J;Helgager J;Reardon DA;Young GS
We describe the imaging findings encountered in GBM patients receiving immune checkpoint blockade and assess the potential of quantitative MRI biomarkers to differentiate patients who derive therapeutic benefit from those who do not. A retrospective analysis was performed on longitudinal MRIs obtained on recurrent GBM patients enrolled on clinical trials. Among 10 patients with analyzable data, bidirectional diameters were measured on contrast enhanced T1 (pGd-T1WI) and volumes of interest (VOI) representing measurable abnormality suggestive of tumor were selected on pGdT1WI (pGdT1 VOI), FLAIR-T2WI (FLAIR VOI), and ADC maps. Intermediate ADC (IADC) VOI represented voxels within the FLAIR VOI having ADC in the range of highly cellular tumor (0.7–1.1 × 10−3 mm2/s) (IADC VOI). Therapeutic benefit was determined by tissue pathology and survival on trial. IADC VOI, pGdT1 VOI, FLAIR VOI, and RANO assessment results were correlated with patient benefit. Five patients were deemed to have received therapeutic benefit and the other five patients did not. The average time on trial for the benefit group was 194 days, as compared to 81 days for the no benefit group. IADC VOI correlated well with the presence or absence of clinical benefit in 10 patients. Furthermore, pGd VOI, FLAIR VOI, and RANO assessment correlated less well with response. MRI reveals an initial increase in volumes of abnormal tissue with contrast enhancement, edema, and intermediate ADC suggesting hypercellularity within the first 0–6 months of immunotherapy. Subsequent stabilization and improvement in IADC VOI appear to better predict ultimate therapeutic benefit from these agents than conventional imaging.
登录
查看更多内容
DOI：
10.1158/1078-0432.ccr-14-0514
发表时间：
2014-10-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Wainwright DA;Chang AL;Dey M;Balyasnikova IV;Kim CK;Tobias A;Cheng Y;Kim JW;Qiao J;Zhang L;Han Y;Lesniak MS
通讯作者：
Lesniak MS
影响因子：
3.1
作者：
Porto, Luciana;Jurcoane, Alina;Hattingen, Elke
通讯作者：
Hattingen, Elke
影响因子：
45.3
作者：
WATLING, CJ;LEE, DH;CAIRNCROSS, JG
通讯作者：
CAIRNCROSS, JG
影响因子：
3.5
作者：
Kralik, S. F.;Taha, A.;Ho, C. Y.
通讯作者：
Ho, C. Y.
DOI：
10.1158/1078-0432.ccr-11-0625
发表时间：
2012-02-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Wieduwilt MJ;Valles F;Issa S;Behler CM;Hwang J;McDermott M;Treseler P;O'Brien J;Shuman MA;Cha S;Damon LE;Rubenstein JL
通讯作者：
Rubenstein JL